Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | AGXT | P21549 | 2/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21685829 | 0.87 | IDO1 (0.53) | IDO1AGXTMAPK14MAOBDHFR | |
| SCHEMBL23555089 | 0.86 | LMNA (0.47) | MAPK14APPALDH1A1 | |
| SCHEMBL1577187 | 0.84 | MCL1 (0.57) | IDO1APPALDH1A1MAOBDHFR | |
| Hydrochloric Acid SCHEMBL7028806 | 0.84 | CACNA1C (0.56) | IDO1AGXTMAPK14ALDH1A1MAOB | |
| SCHEMBL29118568 | 0.84 | ALDH1A1 (0.48) | APPALDH1A1PTGER1 | |
| SCHEMBL18783726 | 0.82 | MAPK14 (0.56) | IDO1AGXTMAPK14ALDH1A1MAOB | |
| SCHEMBL4812827 | 0.81 | APP (0.44) | IDO1MAPK14APPALDH1A1DHFR | |
| SCHEMBL12301131 | 0.80 | MAPK14 (0.55) | IDO1AGXTMAPK14MAOBPTGER1 | |
| Hydrochloric Acid SCHEMBL4809393 | 0.80 | APP (0.43) | IDO1AGXTMAPK14APPALDH1A1 | |
| SCHEMBL6080485 | 0.80 | MAPK14 (0.54) | IDO1AGXTMAPK14MAOBDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230104936-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-4076423-A1 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115087440-A | TRPML modulators | 卡斯玛治疗公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230104936-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | IDO1 2941/4885AGXT 4742/4885MAPK14 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.